Nasrien Ezzeldin Ibrahim, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 63 | 2025 | 11857 | 4.670 |
Why?
|
Natriuretic Peptide, Brain | 17 | 2025 | 1751 | 3.130 |
Why?
|
Stroke Volume | 28 | 2024 | 5620 | 2.340 |
Why?
|
Diabetic Cardiomyopathies | 6 | 2025 | 91 | 1.720 |
Why?
|
Tetrazoles | 5 | 2020 | 922 | 1.380 |
Why?
|
Peptide Fragments | 13 | 2025 | 5152 | 1.320 |
Why?
|
Ventricular Dysfunction, Left | 5 | 2025 | 2145 | 1.120 |
Why?
|
Adrenergic beta-Antagonists | 4 | 2019 | 1244 | 0.990 |
Why?
|
Ventricular Function, Left | 9 | 2025 | 3941 | 0.940 |
Why?
|
Biphenyl Compounds | 7 | 2020 | 1026 | 0.940 |
Why?
|
Angiotensin Receptor Antagonists | 7 | 2020 | 1066 | 0.890 |
Why?
|
Fund Raising | 1 | 2024 | 49 | 0.890 |
Why?
|
Ventricular Remodeling | 4 | 2020 | 1280 | 0.860 |
Why?
|
Coronary Angiography | 7 | 2020 | 4526 | 0.840 |
Why?
|
Natriuretic Peptides | 3 | 2021 | 156 | 0.820 |
Why?
|
Shock, Cardiogenic | 4 | 2022 | 711 | 0.810 |
Why?
|
Cardiovascular Agents | 2 | 2020 | 849 | 0.810 |
Why?
|
Atrial Appendage | 1 | 2023 | 285 | 0.660 |
Why?
|
Baroreflex | 1 | 2020 | 154 | 0.640 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2020 | 208 | 0.640 |
Why?
|
Heart Transplantation | 5 | 2024 | 3291 | 0.620 |
Why?
|
Coronary Stenosis | 4 | 2020 | 803 | 0.600 |
Why?
|
Neprilysin | 3 | 2020 | 487 | 0.590 |
Why?
|
Endothelin-1 | 2 | 2018 | 302 | 0.580 |
Why?
|
Social Justice | 1 | 2022 | 486 | 0.560 |
Why?
|
Drug Combinations | 8 | 2020 | 2079 | 0.550 |
Why?
|
Defibrillators, Implantable | 3 | 2024 | 1498 | 0.540 |
Why?
|
Coronary Artery Disease | 8 | 2023 | 6551 | 0.540 |
Why?
|
Healthcare Disparities | 6 | 2024 | 3412 | 0.530 |
Why?
|
Heart Rate | 2 | 2019 | 4218 | 0.530 |
Why?
|
American Heart Association | 4 | 2024 | 1049 | 0.530 |
Why?
|
Angiography | 3 | 2018 | 1598 | 0.520 |
Why?
|
Cardiology | 7 | 2024 | 1701 | 0.520 |
Why?
|
Renin-Angiotensin System | 2 | 2018 | 735 | 0.510 |
Why?
|
Catheterization | 2 | 2018 | 1431 | 0.510 |
Why?
|
Catheters | 1 | 2018 | 427 | 0.500 |
Why?
|
Atrial Natriuretic Factor | 3 | 2021 | 350 | 0.500 |
Why?
|
Risk Assessment | 12 | 2020 | 24311 | 0.480 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 170 | 0.470 |
Why?
|
Exercise Tolerance | 5 | 2025 | 849 | 0.440 |
Why?
|
Proteomics | 4 | 2020 | 3901 | 0.430 |
Why?
|
Humans | 95 | 2025 | 768451 | 0.430 |
Why?
|
Dyspnea | 2 | 2021 | 1352 | 0.420 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.400 |
Why?
|
Cardiovascular Diseases | 10 | 2024 | 15638 | 0.380 |
Why?
|
Disease Management | 2 | 2021 | 2533 | 0.370 |
Why?
|
Heart Neoplasms | 1 | 2014 | 374 | 0.360 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2017 | 559 | 0.360 |
Why?
|
Acute Kidney Injury | 3 | 2020 | 1943 | 0.360 |
Why?
|
Renal Insufficiency | 1 | 2016 | 809 | 0.350 |
Why?
|
Prognosis | 14 | 2024 | 30028 | 0.350 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2025 | 12242 | 0.340 |
Why?
|
Pericardium | 1 | 2014 | 679 | 0.340 |
Why?
|
Health Status Disparities | 2 | 2024 | 1876 | 0.340 |
Why?
|
Predictive Value of Tests | 11 | 2025 | 15460 | 0.340 |
Why?
|
Peripheral Arterial Disease | 2 | 2018 | 1299 | 0.330 |
Why?
|
Salaries and Fringe Benefits | 2 | 2021 | 262 | 0.310 |
Why?
|
Registries | 6 | 2024 | 8373 | 0.290 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 8051 | 0.290 |
Why?
|
Heart-Assist Devices | 4 | 2022 | 1292 | 0.280 |
Why?
|
Aldehyde Reductase | 2 | 2024 | 70 | 0.280 |
Why?
|
Guideline Adherence | 1 | 2017 | 2239 | 0.270 |
Why?
|
Diuretics | 3 | 2020 | 612 | 0.270 |
Why?
|
Prospective Studies | 16 | 2021 | 54914 | 0.270 |
Why?
|
Troponin | 2 | 2021 | 534 | 0.270 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 1518 | 0.270 |
Why?
|
Middle Aged | 32 | 2025 | 223418 | 0.270 |
Why?
|
Aged | 29 | 2025 | 171520 | 0.270 |
Why?
|
Endothelium, Vascular | 1 | 2018 | 4425 | 0.260 |
Why?
|
Troponin I | 3 | 2020 | 662 | 0.260 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 3708 | 0.260 |
Why?
|
Female | 42 | 2025 | 396943 | 0.250 |
Why?
|
Male | 39 | 2025 | 364781 | 0.250 |
Why?
|
Contrast Media | 1 | 2019 | 5336 | 0.250 |
Why?
|
Atrial Fibrillation | 1 | 2023 | 5162 | 0.230 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2291 | 0.230 |
Why?
|
Artificial Intelligence | 1 | 2019 | 2659 | 0.230 |
Why?
|
Electrocardiography | 1 | 2017 | 6410 | 0.220 |
Why?
|
ROC Curve | 4 | 2021 | 3624 | 0.220 |
Why?
|
Time Factors | 10 | 2025 | 40271 | 0.220 |
Why?
|
United States | 19 | 2024 | 73121 | 0.220 |
Why?
|
Echocardiography | 4 | 2024 | 5043 | 0.220 |
Why?
|
Treatment Outcome | 12 | 2025 | 65409 | 0.210 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5510 | 0.190 |
Why?
|
Asymptomatic Diseases | 1 | 2024 | 591 | 0.180 |
Why?
|
Myocardial Infarction | 5 | 2022 | 11515 | 0.180 |
Why?
|
Research Design | 1 | 2016 | 6217 | 0.180 |
Why?
|
Endorphins | 1 | 2020 | 74 | 0.170 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2024 | 876 | 0.170 |
Why?
|
Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 76 | 0.170 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2024 | 518 | 0.170 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39430 | 0.170 |
Why?
|
Pharmacological Phenomena | 1 | 2019 | 11 | 0.170 |
Why?
|
Exercise Test | 2 | 2024 | 2186 | 0.170 |
Why?
|
Self Efficacy | 1 | 2024 | 651 | 0.160 |
Why?
|
Hyperlipoproteinemias | 1 | 2019 | 20 | 0.160 |
Why?
|
Primary Prevention | 2 | 2024 | 1189 | 0.160 |
Why?
|
Multicenter Studies as Topic | 1 | 2024 | 1727 | 0.160 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2020 | 325 | 0.160 |
Why?
|
Comprehension | 1 | 2024 | 641 | 0.160 |
Why?
|
Glomerular Filtration Rate | 2 | 2018 | 2226 | 0.160 |
Why?
|
Health Literacy | 1 | 2024 | 467 | 0.160 |
Why?
|
Recovery of Function | 2 | 2020 | 2994 | 0.150 |
Why?
|
Risk Factors | 11 | 2020 | 74915 | 0.150 |
Why?
|
Hospital Mortality | 4 | 2024 | 5371 | 0.140 |
Why?
|
Cardiotonic Agents | 1 | 2020 | 544 | 0.140 |
Why?
|
Health Promotion | 2 | 2019 | 2215 | 0.140 |
Why?
|
Apolipoproteins | 1 | 2019 | 328 | 0.140 |
Why?
|
Adenocarcinoma | 1 | 2014 | 6400 | 0.140 |
Why?
|
Cardiovascular System | 1 | 2024 | 838 | 0.130 |
Why?
|
Angiotensins | 1 | 2017 | 141 | 0.130 |
Why?
|
Evaluation Studies as Topic | 1 | 2018 | 1629 | 0.130 |
Why?
|
Reimbursement Mechanisms | 1 | 2021 | 677 | 0.130 |
Why?
|
Glucosides | 1 | 2020 | 532 | 0.130 |
Why?
|
Diabetes Complications | 1 | 2022 | 1322 | 0.130 |
Why?
|
Disease Progression | 5 | 2025 | 13655 | 0.130 |
Why?
|
Practice Guidelines as Topic | 4 | 2024 | 7451 | 0.130 |
Why?
|
Consensus | 5 | 2024 | 3207 | 0.120 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2017 | 330 | 0.120 |
Why?
|
Autonomic Nervous System | 1 | 2020 | 709 | 0.120 |
Why?
|
Chest Pain | 1 | 2022 | 1099 | 0.120 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 1 | 2016 | 152 | 0.120 |
Why?
|
Dyslipidemias | 1 | 2022 | 874 | 0.120 |
Why?
|
Incidence | 5 | 2023 | 21552 | 0.120 |
Why?
|
Cachexia | 1 | 2016 | 202 | 0.120 |
Why?
|
Catheterization, Peripheral | 1 | 2018 | 346 | 0.120 |
Why?
|
Patient Care Management | 1 | 2017 | 304 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2339 | 0.110 |
Why?
|
Kidney Function Tests | 1 | 2016 | 681 | 0.110 |
Why?
|
Antihypertensive Agents | 1 | 2024 | 2028 | 0.110 |
Why?
|
Benzhydryl Compounds | 1 | 2020 | 939 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2016 | 591 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 519 | 0.110 |
Why?
|
Sex Factors | 4 | 2021 | 10647 | 0.110 |
Why?
|
Myocarditis | 1 | 2021 | 804 | 0.110 |
Why?
|
Prevalence | 5 | 2024 | 15880 | 0.110 |
Why?
|
Tissue Donors | 2 | 2021 | 2377 | 0.110 |
Why?
|
Chronic Disease | 3 | 2017 | 9382 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15965 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1915 | 0.110 |
Why?
|
Hypertension | 2 | 2024 | 8611 | 0.100 |
Why?
|
Hospitalization | 3 | 2024 | 10845 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2019 | 964 | 0.100 |
Why?
|
Blood Proteins | 1 | 2018 | 1183 | 0.100 |
Why?
|
Cardiomyopathies | 1 | 2024 | 2056 | 0.100 |
Why?
|
Medication Adherence | 1 | 2024 | 2190 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 730 | 0.100 |
Why?
|
Myocardial Ischemia | 1 | 2022 | 2139 | 0.100 |
Why?
|
Retrospective Studies | 7 | 2024 | 81834 | 0.100 |
Why?
|
Patient Participation | 1 | 2021 | 1450 | 0.100 |
Why?
|
Analysis of Variance | 2 | 2019 | 6242 | 0.090 |
Why?
|
Hepatitis C, Chronic | 1 | 2019 | 1031 | 0.090 |
Why?
|
Adult | 10 | 2024 | 223542 | 0.090 |
Why?
|
Health Status | 2 | 2020 | 4096 | 0.090 |
Why?
|
Cross-Sectional Studies | 6 | 2024 | 26351 | 0.090 |
Why?
|
Stroke | 2 | 2022 | 9791 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2024 | 10784 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2014 | 13589 | 0.080 |
Why?
|
Quality of Life | 2 | 2022 | 13497 | 0.080 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12561 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4049 | 0.080 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2020 | 1482 | 0.080 |
Why?
|
Heart | 2 | 2019 | 4451 | 0.080 |
Why?
|
Patient Selection | 2 | 2022 | 4266 | 0.080 |
Why?
|
Cause of Death | 1 | 2019 | 3727 | 0.080 |
Why?
|
Quality Improvement | 1 | 2023 | 3858 | 0.080 |
Why?
|
Outpatients | 1 | 2016 | 1607 | 0.080 |
Why?
|
Oxygen Consumption | 2 | 2025 | 1882 | 0.070 |
Why?
|
Massachusetts | 2 | 2018 | 8908 | 0.070 |
Why?
|
Survival Analysis | 2 | 2019 | 10125 | 0.070 |
Why?
|
Cohort Studies | 4 | 2019 | 41797 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10358 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2018 | 3145 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2019 | 3063 | 0.070 |
Why?
|
Phenotype | 1 | 2025 | 16712 | 0.070 |
Why?
|
Medicare | 2 | 2021 | 6881 | 0.070 |
Why?
|
Double-Blind Method | 3 | 2024 | 12450 | 0.060 |
Why?
|
Aged, 80 and over | 3 | 2019 | 59680 | 0.060 |
Why?
|
MicroRNAs | 1 | 2021 | 3805 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2016 | 2780 | 0.060 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3682 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14766 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8753 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5887 | 0.060 |
Why?
|
Systole | 1 | 2025 | 938 | 0.050 |
Why?
|
Diastole | 1 | 2025 | 784 | 0.050 |
Why?
|
Apoptosis | 1 | 2018 | 9526 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20231 | 0.050 |
Why?
|
Censuses | 1 | 2022 | 198 | 0.050 |
Why?
|
Electronic Health Records | 1 | 2019 | 4877 | 0.050 |
Why?
|
Telemedicine | 1 | 2018 | 3104 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2022 | 5308 | 0.040 |
Why?
|
Habits | 1 | 2021 | 147 | 0.040 |
Why?
|
Troponin T | 1 | 2025 | 787 | 0.040 |
Why?
|
Telephone | 1 | 2022 | 630 | 0.040 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2024 | 857 | 0.040 |
Why?
|
Kidney Tubules | 1 | 2020 | 448 | 0.040 |
Why?
|
Databases, Factual | 2 | 2024 | 8081 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 341 | 0.040 |
Why?
|
Quinoxalines | 1 | 2019 | 297 | 0.040 |
Why?
|
Delivery, Obstetric | 1 | 2024 | 953 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2020 | 949 | 0.040 |
Why?
|
Terminology as Topic | 1 | 2024 | 1539 | 0.030 |
Why?
|
Animals | 4 | 2022 | 169418 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8730 | 0.030 |
Why?
|
Morbidity | 1 | 2022 | 1760 | 0.030 |
Why?
|
Advisory Committees | 1 | 2021 | 797 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2024 | 1568 | 0.030 |
Why?
|
Podocytes | 1 | 2020 | 402 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2022 | 1734 | 0.030 |
Why?
|
Th17 Cells | 1 | 2021 | 798 | 0.030 |
Why?
|
Sex Distribution | 1 | 2019 | 2286 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3439 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2019 | 682 | 0.030 |
Why?
|
Adiponectin | 1 | 2020 | 1118 | 0.030 |
Why?
|
Waiting Lists | 1 | 2019 | 778 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 864 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2024 | 2959 | 0.030 |
Why?
|
Confidence Intervals | 1 | 2019 | 2932 | 0.030 |
Why?
|
Enzyme Inhibitors | 1 | 2024 | 3734 | 0.030 |
Why?
|
Hepacivirus | 1 | 2019 | 1342 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2021 | 6241 | 0.020 |
Why?
|
Societies, Medical | 1 | 2024 | 3955 | 0.020 |
Why?
|
Internet | 1 | 2024 | 3123 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2019 | 2204 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2021 | 6091 | 0.020 |
Why?
|
Standard of Care | 1 | 2016 | 571 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2016 | 878 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2021 | 18388 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2016 | 904 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1988 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2021 | 2260 | 0.020 |
Why?
|
Hemodynamics | 1 | 2019 | 4202 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3854 | 0.020 |
Why?
|
Blood Pressure | 1 | 2024 | 8538 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9687 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3543 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9558 | 0.020 |
Why?
|
Critical Illness | 1 | 2020 | 2754 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3805 | 0.020 |
Why?
|
Medicaid | 1 | 2019 | 2843 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13026 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2021 | 14480 | 0.020 |
Why?
|
Acute Disease | 1 | 2016 | 7246 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 60045 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14728 | 0.020 |
Why?
|
Boston | 1 | 2018 | 9361 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2018 | 3629 | 0.010 |
Why?
|
Weight Loss | 1 | 2016 | 2710 | 0.010 |
Why?
|
Models, Biological | 1 | 2020 | 9505 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10273 | 0.010 |
Why?
|
Mice | 2 | 2021 | 82045 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9263 | 0.010 |
Why?
|
Survival Rate | 1 | 2017 | 12875 | 0.010 |
Why?
|
Pregnancy | 1 | 2024 | 30179 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7956 | 0.010 |
Why?
|
Obesity | 1 | 2022 | 13065 | 0.010 |
Why?
|
Body Mass Index | 1 | 2016 | 13030 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2020 | 15880 | 0.010 |
Why?
|